1990
Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)
Cedarbaum JM, Silvestri M, Clark M, Toy L, Harts A, Green-Parsons A, McDowell FH. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR). Journal Of Neural Transmission: Parkinson's Disease A And Dementia Section 1990, 2: 205-213. PMID: 2257060, DOI: 10.1007/bf02257651.Peer-Reviewed Original ResearchConceptsStandard SinemetMotor response fluctuationsResponse fluctuationsSinemet CRDisease patientsControlled-release levodopa/carbidopaLevodopa/carbidopaLong-term treatmentParkinson's disease patientsLong-term managementAntiparkinson effectEligible patientsMost patientsMedication dosesInterdose intervalClinical trialsParkinson's diseaseUseful adjunctPatientsSinemetDiseaseYearsCarbidopaAdjunctDoseSustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
Cedarbaum J, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990, 40: 995-7. PMID: 2345621, DOI: 10.1212/wnl.40.6.995.Peer-Reviewed Original ResearchMeSH KeywordsDrug Administration ScheduleDyskinesia, Drug-InducedHumansInfusion PumpsInfusions, ParenteralIntubation, GastrointestinalLevodopaMaleMiddle AgedParkinson DiseaseConceptsInterrupted infusionTherapeutic response fluctuationsStriatal dopamine receptorsContinuous enteral infusionLevodopa dose requirementEnteral administrationEnteral infusionContinuous infusionDopamine receptorsInfusion rateParkinson's diseaseDose requirementsInfusionResponse fluctuationsMotor performanceLevodopaDiseasePatientsAdministrationReceptorsSustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation
Cedarbaum J, Clark M, Toy L, Green‐Parsons A. Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation. Movement Disorders 1990, 5: 298-303. PMID: 1979657, DOI: 10.1002/mds.870050407.Peer-Reviewed Original ResearchConceptsMK-458Disease patientsSelective D2 receptor agonistPostsynaptic dopamine receptorsMotor response fluctuationsD2 receptor agonistParkinson's disease patientsSustained-release formAdjunctive therapyD2 agonistDopamine receptorsSinemetParkinson's diseaseAgonistsResponse fluctuationsProgressive lossPatientsWeeksDiseaseDosageReduced sensitivityDaysTherapyReceptors
1987
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Cedarbaum J, Breck L, Kutt H, McDowell F. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology 1987, 37: 1607-12. PMID: 3658164, DOI: 10.1212/wnl.37.10.1607-a.Peer-Reviewed Original ResearchMeSH KeywordsCarbidopaDelayed-Action PreparationsDrug Administration ScheduleDrug CombinationsHumansLevodopaParanoid DisordersParkinson DiseasePatient Acceptance of Health CareTime FactorsConceptsSinemet CR4Interdose intervalParkinson's diseaseResponse fluctuationsTherapeutic response fluctuationsOpen-label trialPlasma levodopa levelsSlow-release preparationAntiparkinsonian effectsStandard levodopaLevodopa dosesLevodopa preparationsLevodopa levelsDaily dosesRelease preparationDiseaseLevodopaDosesProlongationTreatmentOverall benefitSinemetPatientsSlight reduction
1986
Effect of Supplemental Carbidopa on Bioavailability of l-Dopa.
Cedarbaum J, Kutt H, Dhar A, Watkins S, McDowell F. Effect of Supplemental Carbidopa on Bioavailability of l-Dopa. Clinical Neuropharmacology 1986, 9: 153. PMID: 3085927, DOI: 10.1097/00002826-198604000-00006.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiological AvailabilityCarbidopaDihydroxyphenylalanineDrug Administration ScheduleHumansLevodopaParkinson Disease